Latest news with #RichardPrince
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease
SUMMIT, N.J., June 12, 2025 /PRNewswire/ — Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, Vasceptor® (VAS-101), for the treatment of Sickle Cell Disease (SCD). Orphan Drug Designation is awarded to therapies intended to treat rare diseases that affect fewer than 200,000 people in the United States. This designation provides significant benefits, including seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and exemption from certain FDA fees. 'The attainment of Orphan Drug Designation represents an important regulatory milestone for Vascarta and underscores the therapeutic potential of Vasceptor® to provide safe and effective relief to patients living with this debilitating disease,' said Dr. Richard Prince, CEO & President of Vascarta. 'We plan to work closely with the United States Food & Drug Administration to bring Vasceptor® to market as rapidly as possible.' Dr. Joel Friedman, Professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and Vascarta Scientific Founder & Head, Scientific Advisory Board, stated, 'The preclinical results to date showing pain reduction and therapeutic efficacy resulting from our novel approach of targeting red blood cell instability, neuro-inflammation and vascular inflammation bodes well for the development of a widely accessible therapy that prevents and treats many if not most of the clinical consequences of SCD.' Vasceptor® is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA). About Vasceptor® (VAS-101) VAS-101, developed by Vascarta Inc. (Summit, NJ, USA), is a patented topical curcumin formulation that is delivered using patented transdermal technology and that is designed to overcome the limited bioavailability and suboptimal effectiveness of oral dosing of curcumin. A study in PNAS Nexus suggests VAS-101 may reduce chronic pain, stabilize red blood cells, and lower inflammation in sickle cell disease (SCD). It is currently in a Phase 1 clinical trial at the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida. While curcumin is known for its safety and anti-inflammatory, antioxidant, and anti-sickling properties, its clinical use has been limited by poor oral bioavailability. About Sickle Cell Disease Sickle Cell Disease is the most common inherited genetic disorder that affects primarily African American and non – Hispanic Black individuals in the United States. SCD associated complications include anemia, acute and chronic pain, infections, pneumonia and acute chest syndrome, stroke, kidney, liver, and heart disease. Current estimates indicate there are 175,000 cases of SCD in the USA and 45,000 in European Union countries. The estimated life expectancy of those with sickle cell disease in the USA is more than 20 years shorter than the average expected lifespan. SCD is caused by a single point mutation in the globin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation, oxidative stress, and organ damage, which contributes to the poor quality of life and reduced survival. Recently approved SCD therapies do not mitigate pain, and patients are often on multiple drugs which often have undesirable side effects. The unmet medical need for most SCD sufferers is significant. Better therapies that are safe, improve outcomes, optimize compliance for patients of all ages, minimize the need for blood transfusions, and reduce the need for chronic administration of potentially harmful pain medications are needed. About Vascarta Vascarta Inc. is a clinical stage pharmaceutical company developing efficient transdermal and transmucosal delivery of pharmaceuticals to address inflammatory conditions with an initial focus on Sickle Cell Disease and osteoarthritis. To learn more, contact Vascarta Chairman, CEO & President, Dr. Richard Prince, at rprince@ Media requests should be directed to David Hymson at dhymson@
Yahoo
22-05-2025
- Entertainment
- Yahoo
Richard Prince exhibition 'Posters' on display at Hetzler
May 22—"Posters," a solo exhibition of works by Richard Prince, is on display through Dec. 7 at Hetzler — Marfa, 1976 Antelope Hills Road, in Marfa. One of the foremost representatives of appropriation art, Richard Prince has been recontextualising images and ideas from mass media, advertising and entertainment since the 1970s. Often based on products of everyday American culture, his practice is one of 'post-production,' which reworks cultural phenomena and their attributes to rewrite received narratives and our understanding of history, a news release said. The present exhibition brings together a large body of Prince's "Poster" works on canvas and on paper, created between 2014 and 2024. The large canvases show reproductions of advertisements for mail-order posters, as were often found at the back of magazines in the second half of the 20th century. Hugely popular at the time, these printed images represent touchstones of early counter-cultural magazines, which are among Prince's long-term interests. The motifs of political slogans and far-out art in the form of cheap posters are singled out and chosen by the artist. They find their origins in the hippie head-shop culture of the late '60s, which also encompassed magazines, music and comedy records. Taped-off and blocked-out from the pages where they were listed, the images have been blown up so that the resulting works are far larger than the original posters. In their seemingly arbitrary selection, the poster images combine anti-war slogans, reproductions of Modern art, graphic-design interpretations of nude couples, and pictures of cats in sometimes humorously disparate compilations. The revolutionary attitude of the late '60s student protests is juxtaposed against the self-indulgence of hippie culture in this side-by-side illustration of popular visual language. If cultural attitudes are transported through everyday imagery, then Prince makes them transparent by applying the focus of his artistic practice to these source materials. Method and implication are translated into different contexts and, with his meticulous attention to detail, the artist decodes the communication of contemporary visual language and the ideas which are concealed within it. Richard Prince (b. 1949, Panama Canal Zone) lives and works in Upstate New York. Prince's work has been the subject of numerous solo exhibitions in international institutions, including Georgia Museum of Art, Athens (2024); Louisiana Museum of Art, Humblebaek; The Karpidas Collection (both 2022 — 2023); Museum for Modern Art, Weserburg (2021); Museum of Contemporary Art Detroit (2019 — 2020); Museo de Arte Latinoamericano de Buenos Aires Malba; Espace Louis Vuitton, Beijing; Astrup Fearnley Museet, Oslo (all 2018); Los Angeles County Museum of Art (2017 — 2018); Kunsthaus Bregenz (2014); Picasso Museum, Malaga (2012); Le Consortium, Dijon (2011); Serpentine Gallery, London; Walker Art Center, Minneapolis (both 2008); Guggenheim Museum, New York (2007 — 2008); Kunsthalle Zürich (2002); Museum für Gegenwartskunst, Basel (2001); and MAK, Vienna (2000), among others. The artist participated in the Venice Biennale in 2007 and 2003, as well as the Whitney Biennial in 2004, 1997, 1987 and 1985. Works by Richard Prince are in the collections of international museums including the Art Institute of Chicago; Astrup Fearnley Museet, Oslo; The Broad, Los Angeles; Centre Pompidou, Paris; Fondation Louis Vuitton, Paris; Institute of Contemporary Arts, Boston; Kunstmuseum Basel; Los Angeles County Museum of Art; The Metropolitan Museum of Art, New York; Modern Art Museum of Fort Worth; Museum of Contemporary Art, Chicago; Museum of Contemporary Art, Los Angeles; The Museum of Modern Art, New York; Palazzo Grassi, Pinault Collection, Venice; San Francisco Museum of Modern Art; Solomon R. Guggenheim Museum, New York; Tate, London; Victoria and Albert Museum, London; and Whitney Museum of American Art, New York, among others.
